Details of the Drug
General Information of Drug (ID: DMZ0D3V)
Drug Name |
GRC-6211
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Oxolinic acid; oxolinic acid; 14698-29-4; Nidantin; Prodoxol; Prodoxal; Emyrenil; Dioxacin; Gramurin; Oxolinic; Oksaren; Ossian; Uroxol; Utibid; Urotrate; Uritrate; Pietil; Oxoboi; Ultibid; Starner; Acido oxolinico; Uro-alvar; Acide oxolinique; Acidum oxolinicum; Cistopax; Tiurasin; Orthurine; Acido ossolico; 5-Ethyl-8-oxo-5,8-dihydro-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; NSC-110364; Urinox; Acido ossolico [DCIT]; 5-Ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4-quinolone-3-carboxylic acid; GRC-6127; TRPV1 antagonists (asthma), Glenmark/Lilly; TRPV1 antagonists (incontinence), Glenmark/Lilly; TRPV1 antagonists (pain), Glenmark/Lilly; Transient receptor potential vanilloid sub-family 1 (pain), Glenmark/ Lilly; Vanilloid receptor VR1 antagonists (incontinence/pain/asthma), Glenmark/Lilly
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 377.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
References